By mid-century, the number of people suffering from neurodegenerative diseases is expected to double. With the recent string of late stage clinical trial failures in Alzheimer’s Disease, it is still an open question as to whether treatments can be developed for a disease that is definitively diagnosed post-mortem.
Scientists are coming to realize that the hope for new treatments capable of changing the course of disease lies in developing innovative approaches that deepen our understanding of the early biological underpinnings of neurodegeneration.
Innovation Ventures interviewed three UCSF investigators doing just that.